Original Research| Volume 44, ISSUE 2, e11-25.e8, February 2022

Download started.


Effects of Vitamin D Supplementation on Bone Health and Bone-related Parameters in HIV-infected Patients: A Systematic Review and Meta-analysis


      • Bone health is decreased in individuals with HIV infection.
      • Vitamin D intake may have beneficial effects on skeletal outcomes in HIV patients.
      • Vitamin D supplementation can improve serum 25 (OH) vitamin D in HIV patients.



      There is growing evidence that bone health is decreased in individuals with HIV infection. Vitamin D deficiency is also highly prevalent among HIV-infected patients. The literature was systematically reviewed to determine whether bone health and bone-related parameters may improve with vitamin D supplementation in HIV-infected individuals.


      Four databases were systematically searched for randomized clinical trials of vitamin D supplementation in HIV infection, published from January 1990 to September 2021. No language or publication restrictions were applied. Standardized mean differences (SMD) with 95% CIs are reported. A random-effects model was used to perform meta-analysis.


      Ten studies met the inclusion criteria (N = 733 participants at study completion). The mean ages of the patients in the included trials ranged from 10 to 49 years. The meta-analysis indicated that with vitamin D supplementation, serum 25-hydroxy vitamin D (25[OH]D) level was significantly increased (SMD, 1.86; 95% CI, 1.02 to 2.70; I2 = 94.4%), but there were no significant effects on levels of serum 1,25-dihydroxy vitamin D (1,25-[OH]2D) (SMD, 0.29; 95% CI, –0.07 to 0.64; I2 = 67.4%), total bone mineral density (SMD, 0.07; 95% CI, –0.23 to 0.37; I2 = 00.0%), spine bone mineral density (SMD, 0.15; 95% CI, –0.19 to 0.49; I2 = 17.3%), and parathyroid hormone level (SMD, –0.18; 95% CI, –0.37 to 0.02; I2 = 1.2%) in HIV-infected patients.


      This study showed that vitamin D supplementation can improve serum 25(OH)D in HIV-infected patients. The effects of vitamin D supplementation on other bone health–related parameters such as bone mineral density and parathyroid hormone in HIV-infected patients need to be further investigated in larger-scale, well-designed randomized, controlled trials.

      Graphical abstract

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Danforth K
        • Granich R
        • Wiedeman D
        • Baxi S
        • Padian N.
        Global mortality and morbidity of HIV/AIDS.
        in: Holmes KK Bertozzi S Bloom BR Jha P Major Infectious Diseases. 2017 (Washington, DC)
        • Palella Jr., FJ
        • Baker RK
        • Moorman AC
        • et al.
        Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
        J Acquir Immune Defic Syndr. 2006; 43: 27-34
        • Matovu FK
        • Wattanachanya L
        • Beksinska M
        • Pettifor JM
        • Ruxrungtham K.
        Bone health and HIV in resource-limited settings: a scoping review.
        Curr Opin HIV AIDS. 2016; 11: 306-325
        • Mehsen-Cetre N
        • Cazanave C.
        Osteoarticular manifestations associated with HIV infection.
        Joint Bone Spine. 2017; 84: 29-33
        • Premaor MO
        • Compston JE.
        People living with HIV and fracture risk.
        Osteoporos Int. 2020; 31: 1633-1644
        • Macdonald HM
        • Maan EJ
        • Berger C
        • et al.
        Deficits in bone strength, density and microarchitecture in women living with HIV: a cross-sectional HR-pQCT study.
        Bone. 2020; 138115509
        • Eckard AR
        • McComsey GA.
        Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals.
        Curr HIV/AIDS Rep. 2014; 11: 263-270
        • Mozaffari H
        • Daneshzad E
        • Azadbakht L.
        Dietary carbohydrate intake and risk of bone fracture: a systematic review and meta-analysis of observational studies.
        Public Health. 2020; 181: 102-109
        • Holick MF.
        Vitamin D deficiency.
        N Engl J Med. 2007; 357: 266-281
        • Holick MF
        • Chen TC.
        Vitamin D deficiency: a worldwide problem with health consequences.
        Am J Clin Nutr. 2008; 87: 1080S-1086S
        • Wang H
        • Chen W
        • Li D
        • et al.
        Vitamin D and chronic diseases.
        Aging Dis. 2017; 8: 346
        • Muscogiuri G
        • Altieri B
        • Annweiler C
        • et al.
        Vitamin D and chronic diseases: the current state of the art.
        Arch Toxicol. 2017; 91: 97-107
        • Mansueto P
        • Seidita A
        • Vitale G
        • Gangemi S
        • Iaria C
        • Cascio A.
        Vitamin D deficiency in HIV infection: not only a bone disorder.
        BioMed Res Int. 2015; 2015735615
        • Childs K
        • Welz T
        • Samarawickrama A
        • Post FA.
        Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients.
        AIDS. 2012; 26: 253-262
        • Hsieh E
        • Yin MT.
        Continued interest and controversy: vitamin D in HIV.
        Curr HIV/AIDS Rep. 2018; 15: 199-211
        • Cascio A
        • Colomba C
        • Di Carlo P
        • et al.
        Low bone mineral density in HIV-positive young Italians and migrants.
        PLoS One. 2020; 15e0237984
        • Brown TT
        • Ruppe MD
        • Kassner R
        • et al.
        Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
        J Clin Endocr Metab. 2004; 89: 1200-1206
        • Rovner A
        • Stallings V
        • Rutstein R
        • Schall J
        • Leonard M
        • Zemel B.
        Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial.
        Osteoporosis Int. 2017; 28: 201-209
        • Dhother D
        • Bopitiya D
        • Taha D
        • Das P.
        Effect of low dose oral vitamin D on bone mineral density changes in HIV patients.
        Infect Disord Drug Targets. 2019; 20: 651-658
        • Overton ET
        • Chan ES
        • Brown TT
        • et al.
        Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial.
        Ann Intern Med. 2015; 162: 815-824
        • Eckard AR
        • O'Riordan MA
        • Rosebush JC
        • et al.
        Effects of vitamin D supplementation on bone mineral density and bone markers in HIV-infected youth.
        J Acquir Immune Defic Syndr. (1999). 2017; 76: 539
        • Faber J
        • Bech A
        • van Bentum P
        • Gisolf J
        • Hassing R-J
        • de Boer H.
        Long-term impact of calcium and vitamin D supplementation on bone density in HIV+ patients with documented deficiencies.
        AIDS Res Human Retroviruses. 2020; 36: 58-64
        • Yin MT
        • RoyChoudhury A
        • Bucovsky M
        • et al.
        A randomized placebo-controlled trial of low versus moderate dose vitamin D3 supplementation on bone mineral density in postmenopausal women with HIV.
        J Acquir Immune Defic Syndr (1999). 2019; 80: 342
        • Akimbekov NS
        • Ortoski RA
        • Razzaque MS.
        Effects of sunlight exposure and vitamin D supplementation on HIV patients.
        J Steroid Biochem Mol Biol. 2020; 105664
        • Chokuda E
        • Reynolds C
        • Das S.
        Association of low vitamin D with complications of HIV and AIDS: a literature review.
        Infect Disord Drug Targets. 2020; 20: 122-142
        • da Rocha VM
        • Faria MBB
        • dos Reis Júnior FdA
        • Lima COGX
        • Fiorelli RKA
        • Cassiano KM.
        Use of bisphosphonates, calcium and vitamin D for bone demineralization in patients with human immunodeficiency virus/acquired immune deficiency syndrome: a systematic review and meta-analysis of clinical trials.
        J Bone Metab. 2020; 27: 175
        • Penner J
        • Ferrand RA
        • Richards C
        • Ward KA
        • Burns JE
        • Gregson CL.
        The impact of vitamin D supplementation on musculoskeletal health outcomes in children, adolescents, and young adults living with HIV: a systematic review.
        PLoS One. 2018; 13e0207022
        • Roozbeh F
        • Ghajar M.
        Effect of vitamin D supplementation with anti-viral therapy on CD4 levels in HIV-infected patients: systematic review and meta-analysis.
        Int J Med Investig. 2018; 7: 1-10
        • Visser ME
        • Durao S
        • Sinclair D
        • Irlam JH
        • Siegfried N.
        Micronutrient supplementation in adults with HIV infection.
        Cochrane Database Syst Rev. 2017; CD003650
        • Lin D
        • Rieder MJ.
        Interventions for the treatment of decreased bone mineral density associated with HIV infection.
        Cochrane Database Syst Rev. 2007; CD005645
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DG
        • Group PRISMA
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6e1000097
        • Higgins JP
        • Thomas J
        • Chandler J
        • et al.
        Cochrane Handbook for Systematic Reviews of Interventions.
        John Wiley & Sons, 2019
        • Alshahrani F
        • Aljohani N.
        Vitamin D: deficiency, sufficiency and toxicity.
        Nutrients. 2013; 5: 3605-3616
        • Arpadi SM
        • McMahon DJ
        • Abrams EJ
        • et al.
        Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial.
        Am J Clin Nutr. 2012; 95: 678-685
        • Bang U
        • Kolte L
        • Hitz M
        • et al.
        Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males.
        HIV Clin Trials. 2012; 13: 162-170
        • Boontanondha P
        • Nimitphong H
        • Musikarat S
        • Ragkho A
        • Kiertiburanakul S.
        Vitamin D and calcium supplement attenuate bone loss among HIV-infected patients receiving tenofovir disoproxil fumarate/emtricitabine/efavirenz: an open-label, randomized controlled trial.
        Curr HIV Res. 2020; 18: 52-62
        • Havens PL
        • Stephensen CB
        • Hazra R
        • et al.
        Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.
        Clin Infect Dis. 2012; 54: 1013-1025
        • Kakalia S
        • Sochett EB
        • Stephens D
        • Assor E
        • Read SE
        • Bitnun A.
        Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus.
        J Pediatr. 2011; 159: 951-957
        • Longenecker CT
        • Hileman CO
        • Carman TL
        • et al.
        Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial.
        Antiviral Ther. 2012; 17: 613-621
        • Missailidis C
        • Sørensen N
        • Ashenafi S
        • et al.
        Vitamin D and phenylbutyrate supplementation does not modulate gut derived immune activation in HIV-1.
        Nutrients. 2019; 11: 1675
        • Schall JI
        • Hediger ML
        • Zemel BS
        • Rutstein RM
        • Stallings VA.
        Comprehensive safety monitoring of 12-month daily 7000-IU vitamin D-3 supplementation in human immunodeficiency virus-infected children and young adults.
        J Parenteral Enteral Nutr. 2016; 40: 1057-1063
        • Stallings VA
        • Schall JI
        • Hediger ML
        • et al.
        High-dose vitamin D-3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial.
        Pediatr Infect Dis J. 2015; 34: E32-E40
        • Tan DHS
        • Lee T
        • Raboud J
        • Qamar A
        • Cheung AM
        • Walmsley S.
        Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial.
        HIV Res Clin Pract. 2019; 20: 140-150
        • Hileman CO
        • Overton ET
        • McComsey GA.
        Vitamin D and bone loss in HIV.
        Curr Opin HIV AIDS. 2016; 11: 277-284
        • Jimenez-Sousa MA
        • Martinez I
        • Medrano LM
        • Fernandez-Rodriguez A
        • Resino S.
        Vitamin D in human immunodeficiency virus infection: influence on immunity and disease.
        Front Immunol. 2018; 9: 458
        • Omidian M
        • Mahmoudi M
        • Javanbakht MH
        • et al.
        Effects of vitamin D supplementation on circulatory YKL-40 and MCP-1 biomarkers associated with vascular diabetic complications: a randomized, placebo-controlled, double-blind clinical trial.
        Diabetes & Metabolic Syndrome: Clin Res Rev. 2019; 13: 2873-2877
        • Holick MF
        • Binkley NC
        • Bischoff-Ferrari HA
        • et al.
        Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2011; 96: 1911-1930
        • Shah D
        • Gupta P.
        Vitamin D deficiency: is the pandemic for real?.
        Indian J Community Med. 2015; 40: 215-217
        • Foreman SC
        • Wu PH
        • Kuang R
        • et al.
        Factors associated with bone microstructural alterations assessed by HR-pQCT in long-term HIV-infected individuals.
        Bone. 2020; 133115210
        • Zuccotti G
        • Vigano A
        • Gabiano C
        • et al.
        Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
        Bone. 2010; 46: 1633-1638
        • Hollis BW
        • Wagner CL.
        Clinical review: The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes.
        J Clin Endocrinol Metab. 2013; 98: 4619-4628
        • Chakhtoura M
        • Chamoun N
        • Rahme M
        • Fuleihan GE.
        Impact of vitamin D supplementation on falls and fractures-A critical appraisal of the quality of the evidence and an overview of the available guidelines.
        Bone. 2020; 131115112
        • Siddiqui M
        • Manansala JS
        • Abdulrahman HA
        • et al.
        Immune modulatory effects of vitamin D on Viral Infections.
        Nutrients. 2020; 12: 2879
        • Honma M
        • Ikebuchi Y
        • Suzuki H.
        RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target.
        Pharmacol Ther. 2020; 107682